HCW Biologics Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsHCW Biologics Inc. (HCWB) is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for chronic inflammation-related diseases and selling proprietary compounds as reagents for cell-therapy manufacturing.
What they do
HCW Biologics develops fusion immunotherapeutics using two proprietary platforms, TOBI (Tissue factor-Based fusion) and TRBC (T-cell Receptor Chain constant region), targeting autoimmune disorders, cancer and senescence-associated dysplasia. Its lead clinical candidate is HCW9302, an injectable IL-2 fusion protein complex being tested in a first-in-human Phase 1 trial in alopecia areata. The company has also begun commercializing commercial-ready compounds such as HCW9201 and HCW9206 as reagents used in the production of immunotherapeutics, including CAR-T therapies.
Revenue drivers
- Commercial-ready reagent molecules — HCW9201 and HCW9206 are sold or licensed as reagents for producing cell-based immunotherapeutics; this line produced only $54,232 of revenue in 2025, down from $2.6 million in 2024.
- HCW9302 licensing option — Beijing Trimmune Biotech holds an option to license China-market rights to HCW9302; no revenue from this arrangement is disclosed in the excerpts.
- Corporate partnerships / business development — Management states business development transactions are a key component of its financing and development strategy, but no partnership revenue figures are given in the provided materials.
Recent performance
Annual revenue fell from $2.6 million in 2024 to $54,232 in 2025, and the company reported a net loss of $8.0 million in 2025 versus $30.0 million in 2024. Second-quarter 2026 revenue was $121,730, while the quarter ended March 31, 2026 included $6.5 million of revenue. At June 30, 2026, total assets were $26.8 million, total liabilities $19.3 million, shareholder equity $7.4 million and cash and equivalents $741,324. Operating cash flow was negative $13.4 million in 2025.
Strategy
HCW Biologics is advancing HCW9302, its lead IL-2 fusion protein, through a Phase 1 alopecia areata trial with a full data readout targeted for the fourth quarter of 2026, and it re-acquired ex vivo rights to two commercial-ready molecules from AlloTera Therapeutics in May 2026. The company is seeking a corporate partner to commercialize HCW9206 and similar molecules as reagents for CAR-T manufacturing. Preclinical candidates HCW11-018b (a T-cell engager) and HCW11-040 (a cytokine/pembrolizumab fusion) have IND-enabling activities targeted for 2027. Management describes business development as central to funding and advancing its pipeline.
Risks
- Going concern — The company stated there is substantial doubt about its ability to continue as a going concern based on cash and cash equivalents as of December 31, 2025.
- Material weakness — A material weakness was identified for the year ended December 31, 2025 related to assessing long-lived asset impairment, which could have overstated long-term assets by $1.5 million.
- No approved products / recurring losses — The company has no products approved for commercial sale and has incurred significant losses since inception, with a net loss of $8.0 million in 2025.
- Financing dilution and dependency — Management states it will need additional funding that may not be available on acceptable terms, and raising capital may dilute existing shareholders or require relinquishing valuable rights.
Outlook
Management expects a full Phase 1 clinical data readout for HCW9302 in the fourth quarter of 2026, with patient dosing in the third cohort underway and no dose-limiting toxicities reported. IND-enabling activities for HCW11-018b are targeted for the first half of 2027 and for HCW11-040 in the second half of 2027. The company also continues to pursue a corporate partner to commercialize HCW9206 and related reagent molecules for CAR-T production.